NP-G2-044 (Prilukae)

NP-G2-044 · Novita Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NP-G2-044 (Prilukae), covering 2026-03-09 to 2026-03-09. Get the full timeline:

Most recent: Clinical Trial Update: Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) [Phase 2, Phase 3]

See pricing